Global and regional burdens of oral cancer from 1990 to 2017: Results from the global burden of disease study

Abstract

Background Data on the incidence, mortality, and other burden of oral cancer as well as their secular trends are necessary to provide policy‐makers with the information needed to allocate resources appropriately. The purpose of this study was to use the Global Burden of Disease (GBD) 2017 results to estimate the incidence, mortality, and disability‐adjusted life years (DALYs) for oral cancer from 1990 to 2017. Methods We collected detailed data on oral cancer from 1990 to 2017 from the GBD 2017. The global incidence, mortality, and DALYs attributable to oral cancer as well as the corresponding age‐standardized rates (ASRs) were calculated. The estimated annual percentage changes in the ASRs of incidence (ASRI) and mortality (ASRM) and age‐standardized DALYs of oral cancer were also calculated according to regions and countries to quantify the secular trends in these rates. Results We tracked the incidence, mortality, and DALYs of oral cancer in 195 countries/territories over 28 years. Globally, the incidence, mortality, and DALYs of oral cancer increased by about 1.0‐fold from 1990 to 2017. The ASRI of oral cancer showed a similar trend, increasing from 4.41 to 4.84 per 100,000 person‐years during the study period. The ASRM remained approximately stable at about 2.4 per 100,000 from 1990 to 2017, as did the age‐standardized DALYs, at about 64.0 per 100,000 person‐years. ASRI was highest in Pakistan (27.03/100,000, 95% CI = 22.13‐32.75/100,000), followed by Taiwan China, and lowest in Iraq (0.96/100,000, 95% CI = 0.86‐1.06/100,000). ASRM was highest in Pakistan (16.85/100,000, 95% CI = 13.92‐20.17/100,000) and lowest in Kuwait (0.51/100,000, 95% CI = 0.45‐0.58/100,000). Conclusions The ASRI of oral cancer has increased slightly worldwide, while the ASRM and age‐standardized DALY have remained stable. However, these characteristics vary between countries, suggesting that current prevention strategies should be reoriented, and much more targeted and specific strategies should be established in some countries to forestall the increase in oral cancer.

Leukemia incidence trends at the global, regional, and national level between 1990 and 2017

“…The GBD study provides a tool to quantify health loss from hundreds of diseases, injuries, and risk factors so that health systems can be improved and disparities eliminated [11]. Data from the GBD study have also been widely used to learn the disease burden of cancer [12][13][14][15][16]. In the GBD study framework, the cancer incidence data were retrieved from individual cancer registries or aggregated databases of cancer registry data, such as "Cancer Incidence in Five Continents" (CI5), EUREG, or NORDCAN.…”

Bacteriocins: Potential for Human Health

“…Cancer is a major public health problem worldwide and is the leading cause of death in the global [ 50 ]. Although there have been new breakthroughs in cancer research in recent years, there are still many challenges that need to be addressed, and the prevention and treatment of cancer need to be further explored continuously.…”

Resveratrol inhibited the metastatic behaviors of cisplatin‐resistant human oral cancer cells via phosphorylation of ERK/p‐38 and suppression of MMP‐2/9

“…Oral squamous cell carcinoma (OSCC) is the most common head and neck cancer with more than 500,000 newly diagnosed cases every year (Siegel et al, 2020). Globally, both the incidence and the mortality of oral cancer have doubled from 1990 to 2017 (Ren et al., 2020). Clinically, primary surgery is the most effective therapeutic strategy for early‐stage OSCC, while chemotherapy and concurrent chemoradiotherapy are frequently used in patients with advanced OSCC.…”